Annette Staebler
Papers
1
Total Citations
40
H-Index
1
About
Dr. Annette Staebler is a leading pathologist whose research focuses on the molecular characterization of gynecologic cancers, particularly ovarian carcinoma. Her major contributions center on translating complex genomic alterations into actionable clinical biomarkers. In her landmark 2022 study, "Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort," Dr. Staebler evaluated HRD status in 514 ovarian tumor samples using next-generation sequencing. This work, which has garnered 40 citations, demonstrated the critical role of BRCA1/BRCA2 mutations and broader genomic instability in defining targeted therapy strategies for patients. By bridging the gap between laboratory diagnostics and real-world clinical application, she has helped establish HRD testing as a standard for guiding PARP inhibitor treatment. Her research has profound implications for personalized medicine in oncology, enabling more precise identification of patients who will benefit from DNA repair-targeted therapies. Dr. Staebler’s work exemplifies how rigorous pathological analysis can directly improve treatment outcomes in aggressive cancers.
Research Focus
Key Achievements
Top Papers
- 1